BGI Joins with Clearbridge BioMedics to Develop Liquid Biopsy in China

BGI, the Shenzhen "omics" company, has partnered with Singapore's Clearbridge BioMedics to distribute and develop its liquid biopsy product in greater China. CBB's ClearCell ® FX1 product separates circulating tumor cells (CTC) from the blood. BGI intends to use its expertise, which stretches from genomics to trans-omics, to develop a product that provides clinical insights from a blood draw for clinical and research use, furthering personalized medicine. The machine adds to BGI's offerings in the clinical diagnostics market. More details.... Share this with colleagues: // //